GXV813 for acute schizophrenia symptoms
About this title
Read the official source — NCT07467993Researchers are comparing GXV813 and placebo to find out how the approaches affect psychotic symptoms in adults with schizophrenia.
Understand this study
What is this study about?
Researchers are comparing GXV813 and placebo to find out how the approaches affect psychotic symptoms in adults with schizophrenia.
Who could participate?
This study is for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.
- Listed locations
- Bentonville and 15 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 142
- Sponsor
- Novartis Pharmaceuticals
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States, Bulgaria
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT07467993
- Official title
Show the full official title
A Phase 2a, Randomized, Participant- and Investigator- Blinded, Parallel-group, Placebo-controlled, Multicenter Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With DSM-5 Schizophrenia (STAR-1)
Recruitment & locations
Bentonville, United States · Pico Rivera, United States · Miami, United States
11 more locations
- Decatur, United States
- Chicago, United States
- St Louis, United States
- Sofia, Bulgaria
- Haskovo, Bulgaria
- Kazanlak, Bulgaria
- Lovech, Bulgaria
- Plovdiv, Bulgaria
- Sliven, Bulgaria
- Veliko Tarnovo, Bulgaria
- Vratsa, Bulgaria
Interested in joining this study?
Questions about this study
What is this study about?
Researchers are comparing GXV813 and placebo to find out how the approaches affect psychotic symptoms in adults with schizophrenia.
Who is behind this study?
The study sponsor is Novartis Pharmaceuticals.
Does this study involve medication?
Yes. The study involves medication, including GXV813 and Placebo.
Who can participate?
This study is for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as recruiting.
